ArticleCancers2019
Diagnostic and Prognostic Value of
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- A scoping review of DNA methylation biomarkers for non-invasive detection of colorectal cancer at the CpG site level.Clinical epigenetics · 2026Article
- β1,4-galactosyltransferase III drives retinoblastoma invasion via activation of integrin-FAK axis.Cell death & disease · 2026Article
- Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.World journal of gastroenterology · 2024Article
- Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis.International journal of molecular sciences · 2024Review
- Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.Disease markers · 2024Review
- Machine learning-based identification of proteomic markers in colorectal cancer using UK Biobank data.Frontiers in oncology · 2024Article
- Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.Frontiers in immunology · 2024Article
- Identification of GUCA2A and COL3A1 as prognostic biomarkers in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation.Scientific reports · 2023Article
- Review
- Article
- Significance of Hypermethylation of Tumor-Suppressor Genes PTGER4 and ZNF43 at CpG Sites in the Prognosis of Colorectal Cancer.International journal of molecular sciences · 2022Article
- Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy.Current issues in molecular biology · 2022Review
- Colorectal liver metastasis: molecular mechanism and interventional therapy.Signal transduction and targeted therapy · 2022Review
- Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer.Scientific reports · 2021Article
- High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.Clinical epigenetics · 2021Article
- Identifying Novel Actionable Targets in Colon Cancer.Biomedicines · 2021Review
- Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.Clinical epigenetics · 2021Review
- Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.Gastroenterology · 2021Review
- Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer.World journal of surgical oncology · 2021Article
- Construction and Comprehensive Prognostic Analysis of a lncRNA-miRNA-mRNA Regulatory Network and Tumor Immune Cell Infiltration in Colorectal Cancer.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 3 countries.
Francesco PicardoLaboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, 00128 Rome, Italy. f.picardo@unicampus.it.
Antonella RomanelliDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy. romanelli.antonella@gmail.com.
Laura Muinelo-RomayLiquid Biopsy Analysis Unit, Translational Medical Oncology Group (Oncomet), CIBERONC, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain. laura.muinelo.romay@sergas.es.
Tommaso MazzaUnit of Bioinformatics, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. t.mazza@css-mendel.it.ORCID 0000-0003-0434-8533
Caterina FusilliUnit of Bioinformatics, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. caterinafusilli@gmail.com.
Paola ParrellaLaboratory of Oncology, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. pparrella@operapadrepio.it.ORCID 0000-0001-6031-9636
Jorge BarbazánLiquid Biopsy Analysis Unit, Translational Medical Oncology Group (Oncomet), CIBERONC, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain. jorgebarbazan@gmail.com.ORCID 0000-0002-7165-8497
Rafael Lopez-LópezLiquid Biopsy Analysis Unit, Translational Medical Oncology Group (Oncomet), CIBERONC, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain. rafael.lopez.lopez@sergas.es.
Raffaela BarbanoLaboratory of Oncology, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. r.barbano@operapadrepio.it.
Mariangela De RobertisInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Consiglio Nazionale delle Ricerche (CNR), 70126 Bari, Italy. mariangela.derobertis@gmail.com.ORCID 0000-0002-5409-639X
Chiara TaffonUnit of Pathology, University Campus Bio-Medico of Rome, 00128 Rome, Italy. c.taffon@unicampus.it.
Veronica BordoniCellular Immunology and Pharmacology Laboratory, "Lazzaro Spallanzani" National Institute for Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00149 Rome, Italy. veronica.bordoni@inmi.it.
Chiara AgratiCellular Immunology and Pharmacology Laboratory, "Lazzaro Spallanzani" National Institute for Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00149 Rome, Italy. chiara.agrati@inmi.it.
Manuela CostantiniDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy. m.costantini@unicampus.it.ORCID 0000-0003-1638-0987
Francesca RicciLaboratory of Pathology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy. francesca.ricci@idi.it.
Paolo GrazianoPathology Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. p.graziano@operapadrepio.it.ORCID 0000-0001-7066-7896
Evaristo MaielloDepartment of Oncology, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. e.maiello@operapadrepio.it.
Lucia Anna MuscarellaLaboratory of Oncology, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (Fg), Italy. l.muscarella@operapadrepio.it.ORCID 0000-0002-1866-8151
Vito Michele FazioLaboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, 00128 Rome, Italy. fazio@unicampus.it.
Maria Luana PoetaDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy. marialuana.poeta@uniba.it.
Casa Sollievo della Sofferenza · ITUniversità Campus Bio-Medico · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITServicio Gallego de Salud · ESUniversity of Bari Aldo Moro · ITInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Dermopatico dell'Immacolata · ITUniversité Paris Sciences et Lettres · FR
Funding
Associazione Italiana per la Ricerca sul Cancro MFAG10520
Abstract
Epigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene
Indexed as
B4GALT1cetuximabcfDNAcolorectal cancerliquid biopsypredictive biomarker
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.